BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9609635)

  • 1. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.
    Bauer JJ; Srivastava S; Connelly RR; Sesterhenn IA; Preston DM; McLeod DG; Moul JW
    Urology; 1998 Jun; 51(6):970-6. PubMed ID: 9609635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
    Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
    J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.
    Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW
    Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.
    Stapleton AM; Zbell P; Kattan MW; Yang G; Wheeler TM; Scardino PT; Thompson TC
    Cancer; 1998 Jan; 82(1):168-75. PubMed ID: 9428494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
    Stackhouse GB; Sesterhenn IA; Bauer JJ; Mostofi FK; Connelly RR; Srivastava SK; Moul JW
    J Urol; 1999 Dec; 162(6):2040-5. PubMed ID: 10569564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathologic characteristics of familial prostate cancer in Asian population.
    Kim M; Kim JK; Ye C; Lee H; Oh JJ; Lee S; Jeong SJ; Lee SE; Hong SK; Byun SS
    Prostate; 2020 Jan; 80(1):57-64. PubMed ID: 31664733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial prostate cancer: a different disease?
    Kupelian PA; Klein EA; Witte JS; Kupelian VA; Suh JH
    J Urol; 1997 Dec; 158(6):2197-201. PubMed ID: 9366343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Connelly RR; Moul JW
    J Urol; 1998 Aug; 160(2):459-65. PubMed ID: 9679898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial and hereditary prostate cancer by definition in an italian surgical series: clinical features and outcome.
    Sacco E; Prayer-Galetti T; Pinto F; Ciaccia M; Fracalanza S; Betto G; Pagano F
    Eur Urol; 2005 Jun; 47(6):761-8. PubMed ID: 15925070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.
    Grossfeld GD; Carroll PR; Lindeman N; Meng M; Groshen S; Feng AC; Hawes D; Cote RJ
    Urology; 2002 Jan; 59(1):97-102. PubMed ID: 11796289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases.
    Azzouzi AR; Valeri A; Cormier L; Fournier G; Mangin P; Cussenot O
    Urology; 2003 Jun; 61(6):1193-7. PubMed ID: 12809896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
    Bauer JJ; Connelly RR; Seterhenn IA; Deausen J; Srivastava S; McLeod DG; Moul JW
    J Urol; 1998 Mar; 159(3):929-33. PubMed ID: 9474185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.